摘要
目的观察毒痰瘀脾虚方含药血清对HepG2肝癌细胞增殖及血管内皮生长因子(VEGF)的影响。方法制备wistar大鼠含药及空白血清,体外培养肝癌HepG2细胞,设空白对照组、索拉非尼含药血清组、毒痰瘀脾虚方含药血清组。通过CCK8法,比较毒痰瘀脾虚方含药血清在不同浓度及不同作用时间对细胞增殖活性的影响;采用ELISA法,观察毒痰瘀脾虚方含药血清对HepG2细胞VEGF表达的影响。结果CCK8检测结果显示,毒痰瘀脾虚方含药血清能明显抑制肝癌HepG2细胞的增殖活性,且具有明显的浓度依耐性和时间依耐性,与空白对照组相比,差异具有显著统计学意义(P<0.01);ELISA检测结果显示,毒痰瘀脾虚方含药血清能明显抑制HepG2细胞VEGF的表达,与空白对照组相比,差异具有显著统计学意义(P<0.01)。结论毒痰瘀脾虚方含药血清能抑制HepG2细胞的增殖活性,下调HepG2细胞的VEGF的表达,具有抑制肿瘤血管生成的作用。
Objective To observe the effect of drug-containing serum of Dutanyu Pixu Formulae on the proliferation of HepG2 hepatocellular carcinoma cells and the expression of vascular endothelial growth factor(VEGF).Methods Wistar rat drug-containing serum and blank serum were prepared,and HepG2 cells of human liver cancer were cultured in vitro.The cells were divided into blank control group,sorafenib drug-containing group and drug-containing serum of Dutanyu Pixu Formulae group.CCK8 method was used to detect the effect of drug-containing serum of Dutanyu Pixu Formulae on cell proliferative activity at the different concentration and at different time.VEGF expression in cell culture supernatant was detected by ELISA.Results CCK8 test results showed that the drug-containing serum of Dutanyu Pixu Formulae could significantly inhibit the proliferative activity of cells,and it had significant concentration and time-dependent tolerance.The difference was statistically significant compared with the blank control group(P<0.01).ELISA results showed that the drug-containing serum of Dutanyu Pixu Formulae could significantly inhibit the expression of VEGF in HepG2 cells,and the difference was statistically significant compared with that in the blank control group(P<0.01).Conclusion The drug-containing serum of Dutanyu Pixu Formulae can inhibit the proliferative activity of HepG2 cells,down-regulate the expression of VEGF in HepG2 cells,and inhibit tumor angiogenesis.
作者
潘谊
吴辉坤
PAN Yi;WU Huikun(Hubei University of Traditional Chinese Medicine,Wuhan 430065,China;Hubei Institute of Traditional Chinese Medicine,Wuhan 430074,China;Hubei Provincial Hospital of Traditional Chinese Medicine,Wuhan 430061,China)
出处
《吉林中医药》
2020年第12期1638-1641,共4页
Jilin Journal of Chinese Medicine
基金
国家中医药管理局国家中医临床研究基地业务建设科研专项课题“基于毒痰瘀虚证候要素的H22肝癌荷瘤小鼠方证相关研究”(JDZX2015177)。
作者简介
潘谊(1992-),女,硕士研究生,主要从事中医药防治结石及肝胆病的研究;通信作者:吴辉坤,电话-18986033451,电子信箱-621120216@qq.com。
